Huisheng Bio released its 2026 interim report, with net profit attributable to the parent company of 206 million yuan, up 75.59% from the same period last year. Total operating revenue was 865 million yuan, up 5.20% year-on-year, and net operating cash inflow was 128 million yuan, up 3.57% year-on-year. The company's latest gross margin was 35.72%, rising for six consecutive quarters, and its latest return on equity was 8.89%, up 3.20 percentage points from the same period last year. Diluted earnings per share were 1.02 yuan, up 53.56% year-on-year.
Wuhan Hvsen Biotechnology Co LtdNet profit up 75.59% year-on-year, with improved margins and ROE.